Abstract:The aim of this study was to determine, in a Phase I/II clinical trial, the pharmacokinetics, dosimetry and toxicity, as well as antitumor activity, of the I-131-labeled murine anti-carcinoembryonic antigen (CEA) monoclonal antibody, NP-4 (IgG(1) subtype). Methods: A total of 57 patients with CEA-expressing tumors (29 colorectal, 9 lung, 7 pancreas, 6 breast and 4 medullary thyroid cancer patients), mostly in very advanced stages, were treated. The patients underwent a diagnostic study (1-3 mg of IgG and 8-30 mCi of I-131) to assess tumor targeting and to estimate dosimetry, followed by the therapeutic dose (4-23 mg and 44-268 mCi), based on the radiation dose to the red marrow. Imaging was performed from 4-240 hr postinjection (planar and SPECT). Blood and whole-body clearance were determined; radiation doses were calculated by the Medical Internal Radiation Dose scheme. Results: Red marrow doses ranged from 45 to 706 cGy, and whole-body doses ranged from 31 to 344 cGy. Differences in pharmacokinetics were found between different types of CEA-producing tumors: blood T-1/2 was significantly lower in colorectal cancer when compared to all other tumor types (21.4 +/- 11.1 hr versus 35.8 +/- 13.2 hr; p < 0.01), as was also whole-body t(1/2). Myelotoxicity was dose-limiting, and its severity was related to the types of prior therapy and extent of bone marrow involvement. In patients without prior radiation or chemotherapy, marrow doses as high as 600 cGy were tolerated without evidence of dose-limiting toxicity. No major toxicity to other organs was observed. Tumor doses were inversely related to the tumor mass and ranged between 2 and 218 cGy/mCi. Modest antitumor effects were seen in 12 of 35 assessable patients (1 partial remission, 4 minor/mixed responses and 7 with stabilization of previously rapidly progressing disease). Conclusion: These results suggest that prior chemotherapy or external beam radiation is an important risk factor for the development oi hematological toxicity in radioimmunotherapy and that higher radiation doses may be delivered to tumors of patients without prior therapy compromising the bone marrow reserve. The different and, in the individual cases, unpredictable clearance rates suggest the necessity of dosimetry-based treatment planning rather than mCi/m(2) dosing. Small tumors seem to be more suitable for radioimmunotherapy because of their favorable dosimetry, but to achieve better therapeutic results in patients with bulky disease, the application of higher, potentially myeloablative doses is indicated.

Fractionated Radioimmunotherapy Using Low Doses of Iodine-131 Labeled Anti-Cea Monoclonal Antibody after Tumor Volume Reduction.

Radioimmunotherapy of human colon cancer xenografts by using 131I labeled-CAb1 F(ab')2.

Radioimmunotherapy Of Human Colon Cancer Xenografts With I-131-Labeled Anti-Cea Monoclonal Antibody

Radioimmunotherapy of Human Colon Cancer Xenografts with<sup>131</sup>I-Labeled Anti-CEA Monoclonal Antibody

Local Radioimmunotherapy of Breast Cancer-Bearing Nude Mice Using Anti-Cea Monoclonal Antibody C50 Labeled with 131I

Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.

Radioimmunotherapy of human colon cancer xenografts by using {sup 131}I labeled-CAb{sub 1} F(ab'){sub 2}

Radioimmunotherapy of human colon cancer xenografts with 131I-labeled anti-CEA monoclonal antibody.

Radioimmunoimaging and Targeting Treatment in an Immunocompetent Murine Model of Triple-Negative Breast Cancer Using Radiolabeled Anti-Programmed Death-Ligand 1 Monoclonal Antibody

Enhanced Tumor Inhibiting Effect of 131I-Bdi-1-based Radioimmunotherapy and Cytosine Deaminase Gene Therapy Modulated by a Radio-Sensitive Promoter in Nude Mice Bearing Bladder Cancer

Radiofrequency Ablation Before Intratumoral Injection of 131I-Chtnt Improves the Tumor-to-Normal Tissue Ratio in Solid VX2 Tumor

[Research on Radioimmunotherapy of Lung Cancer in Nude Mice Using Lung Cancer Monoclonal Antibody LC-1 Combined with ⁹⁰Y].

Variables Influencing Tumor Dosimetry in Radioimmunotherapy of CEA-expressing Cancers with Anti-Cea and Antimucin Monoclonal Antibodies.

Evaluation of Therapeutic Effectiveness Of131i-Antiegfr-bsa-pcl in a Mouse Model of Colorectal Cancer

Experimental Study for the Targeting Therapy of Mouse Lung Carcinoma Treated by Anti-hnRNPB1 Monoclonal Antibody with 131I

Radioimmunolocalization and blodistribution of 131Ⅰ labeled anti-CEA,TPS and mixture monoclonal antibody in nude mice bearing human breast cancer xenografts

Research on Radioimmunotherapy of Lung Cancer in Nude Mice Using Lung Cancer Monoclonal Antibody LC-1 Combined with 90Y

Experimental Study of Targeting Therapy of Lung Carcinoma in Mice with 131I Combined Hnrnp B1 Monoclonal Antibody

Adjuvant radioimmunotherapy improves survival of rats after resection of colorectal liver metastases

131 I-chTNT-mediated Radioimmunotherapy for Non-Uptaking 131 I Pulmonary Metastases from Differentiated Thyroid Carcinoma

Radioimmunoimaging and Biodistribution of ~(131)I Labeled Anti-Cea Monoclonal Antibody C50 in Nude Mice Bearing Human Breast Carcinoma Xenografts